Finance
Mylan stock dropped 7% after second quarter sales slumped (MYL)
- Mylan’s stock dropped 7.4% shortly after markets opened on Wednesday due to poor second quarter earnings.
- The company’s total revenue for the second quarter was $2.8 billion, down 5% compared to last year. Sales in North America also fell 22%.
- Mylan then announced that it was going to conduct a strategic review of the company, saying it believes it is undervalued. This means the company could be broken up or sold.
- Mylan N.V. is an American pharmaceutical company registered in the Netherlands that makes both generic and specialty drugs. It is best known as the manufacturer of EpiPen.
Continue Reading
-
Business7 days ago
API startup Noname Security nears $500M deal to sell itself to Akamai
-
Entertainment6 days ago
NASA discovered bacteria that wouldn’t die. Now it’s boosting sunscreen.
-
Entertainment7 days ago
How to watch ‘Argylle’: When and where is it streaming?
-
Business6 days ago
Tesla drops prices, Meta confirms Llama 3 release, and Apple allows emulators in the App Store
-
Business5 days ago
TechCrunch Mobility: Cruise robotaxis return and Ford’s BlueCruise comes under scrutiny
-
Entertainment5 days ago
‘The Sympathizer’ review: Park Chan-wook’s Vietnam War spy thriller is TV magic
-
Business4 days ago
Tesla layoffs hit high performers, some departments slashed, sources say
-
Business4 days ago
Meta to close Threads in Turkey to comply with injunction prohibiting data-sharing with Instagram